Navigating US payer evidence needs to optimise market access

Pharma Market Access Insights - from Mtech Access

What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?
In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.
We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.
They explore:

• The evolving payer evidence landscape in the US
• Preferences for clinical and economic evidence by US payers
• Key differences between the US and other global markets with regard to evidence, HEOR, and market access
• Opportunities and challenges when launching new medicines/medical devices/diagnostics in the US
• Innovative perspectives on evidence planning and strategy for the US market
• US payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer survey

This episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/
Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/
Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

章节

1. Welcome and introductions (00:00:00)

2. What do we mean when we talk about payers in the US? (00:03:34)

3. Do US payers evaluate clinical effectiveness and economic considerations in a similar way to European HTA bodies? (00:09:41)

4. How impactful are ICER's evaluations? (00:13:09)

5. Why is the US often the first launch market for Pharma and MedTech innovations? (00:16:12)

6. What type of evidence is required by US payers? (00:20:29)

7. What are the similarities and differences when preparing for a MedTech or Medical Device launch versus a Pharma product? (00:28:35)

8. How can companies ensure they have the right evidence and tools to engage with payer bodies in the US? (00:30:22)

9. What changes are happening that our audience should be aware of? (00:38:40)

10. Opportunities for Pharma and MedTech companies launching new products in the US (00:48:49)

11. What recommendations would you make to a company launching a product in the US for the first time? (00:51:18)

12. Insights from US payer survey report (00:54:58)